 Home > Active Ingredient News > Antitumor Therapy > J Clin Invest: MEK inhibitor cobimetinib combined with PD-L1 inhibitor atezolizumab prolongs PFS in biliary tract cancer (BTC)

J Clin Invest: MEK inhibitor cobimetinib combined with PD-L1 inhibitor atezolizumab prolongs PFS in biliary tract cancer (BTC)

 Last Update: 2022-01-23
 Source: Internet
 Author: User

Tags

brain energy source

phase 5 band

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

MEK inhibitors have limited activity in biliary tract cancer (BTC) as monotherapy, but appear to enhance activity against programmed death ligand 1 (PD-L1) pathway inhibition

This open-label phase II study (NCT03201458) randomized patients with BTC to atezolizumab (anti-PD-L1) monotherapy or in combination with cobimetinib (MEK inhibitor)

From February 2018 to October 2018, 77 patients were enrolled with atezolizumab (n = 39) or atezolizumab + cobimetinib (n = 38)

The trial met its primary endpoint, with a median PFS of 3.

PFS

The ORRs of the combination and single-agent groups were 3.

Efficacy assessment

TRAEs of any grade occurred similarly in the two groups, with 33 (84.

AEs

Taken together, the study showed that atezolizumab + cobimetinib combination therapy prolonged PFS compared with atezolizumab monotherapy, but the low response rates in both groups also indicated the immune- tolerant properties of BTC

Original Source: Original Source:

Yarchoan M, Cope L, Ruggieri AN, Anders RA, Noonan AM, Goff LW, Goyal L, Lacy J, Li D, Patel AK, He AR, Abou-Alfa GK, Spencer K, Kim EJ, Davis SL, McRee AJ, Kunk PR, Goyal S, Liu Y, Dennison L, Xavier S, Mohan AA, Zhu Q, Wang-Gillam A, Poklepovic A, Chen HX, Sharon E, Lesinski GB, Azad NS.
Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers.
J Clin Invest.
2021 Dec 15;131(24):e152670.
doi: 10.
1172/JCI152670.
PMID: 34907910; PMCID: PMC8670844.

Leave a comment here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.